The BioVac Institute, a state-backed
South African vaccine company, plans to use a deal it won to manufacture
coronavirus vaccines. The contract with
American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in
South Africa[3]
ImmunityBio and
BioVac plan to distribute the vaccines throughout
South Africa and Africa.[4][5]
History
In April 2020, a product developed by ImmunityBio was rumoured to be a potential
SARS-CoV-2 coronavirus vaccine.[6]
On 1 June 2020, the product was selected for inclusion on the
Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from the
Food and Drug Administration to begin an initial safety trial in humans in June 2020."[7]
The BioVac Institute, a state-backed
South African vaccine company, plans to use a deal it won to manufacture
coronavirus vaccines. The contract with
American based ImmunityBio Inc is currently conducting phase 1 vaccine trials in
South Africa[3]
ImmunityBio and
BioVac plan to distribute the vaccines throughout
South Africa and Africa.[4][5]
History
In April 2020, a product developed by ImmunityBio was rumoured to be a potential
SARS-CoV-2 coronavirus vaccine.[6]
On 1 June 2020, the product was selected for inclusion on the
Operation Warp Speed subsidy list, in order to fund monkey trials.[7] The company "hope to receive approval from the
Food and Drug Administration to begin an initial safety trial in humans in June 2020."[7]